Skip to main content
Fig. 4 | Critical Care

Fig. 4

From: Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients

Fig. 4

Receiver operating curves (ROC) of procalcitonin (PCT) and C-reactive protein (CRP) in the group of patients treated with dexamethasone but not with tocilizumab (D+T− group, a and b), the D+T+ group (c and d), and in all patients of the second cohort (D+T−/+ group, e and f) to illustrate sensitivity and specificity to predict the occurrence of a secondary infection in critically ill COVID-19 patients. Binned data of PCT and CRP of days − 1 and 0 were used for these analyses. The grey lines illustrate the previously published ROCs of D−T− patients [5]. p values reflect differences between the two areas under the receiver operating curves (AUROCs). Positive predictive value (PPV) and negative predictive value (NPV) are provided for the concentrations of PCT and CRP indicated by the arrows

Back to article page

Critical Care

ISSN: 1364-8535